These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21903115)

  • 21. A metabotropic glutamate 2/3 receptor antagonist, MGS0039, increases extracellular dopamine levels in the nucleus accumbens shell.
    Karasawa J; Yoshimizu T; Chaki S
    Neurosci Lett; 2006 Jan; 393(2-3):127-30. PubMed ID: 16233956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prodrugs of 3-(3,4-dichlorobenzyloxy)-2-amino-6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (MGS0039): a potent and orally active group II mGluR antagonist with antidepressant-like potential.
    Yasuhara A; Nakamura M; Sakagami K; Shimazaki T; Yoshikawa R; Chaki S; Ohta H; Nakazato A
    Bioorg Med Chem; 2006 Jun; 14(12):4193-207. PubMed ID: 16487713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
    Koike H; Iijima M; Chaki S
    Behav Brain Res; 2011 Oct; 224(1):107-11. PubMed ID: 21669235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity.
    Galici R; Echemendia NG; Rodriguez AL; Conn PJ
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1181-7. PubMed ID: 16123306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 5-HT
    Fukumoto K; Iijima M; Funakoshi T; Chaki S
    Neuropharmacology; 2018 Jul; 137():96-103. PubMed ID: 29738849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of c-Fos induction in the brain by the mGlu2/3 receptor antagonist LY341495 and agonist LY354740: evidence for widespread endogenous tone at brain mGlu2/3 receptors in vivo.
    Linden AM; Bergeron M; Schoepp DD
    Neuropharmacology; 2005; 49 Suppl 1():120-34. PubMed ID: 16023151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant].
    Chaki S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Aug; 32(4):219-26. PubMed ID: 23012890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors.
    Gewirtz JC; Chen AC; Terwilliger R; Duman RC; Marek GJ
    Pharmacol Biochem Behav; 2002 Sep; 73(2):317-26. PubMed ID: 12117585
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats.
    Yoshimizu T; Shimazaki T; Ito A; Chaki S
    Psychopharmacology (Berl); 2006 Jul; 186(4):587-93. PubMed ID: 16612616
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activation of mGlu2/3 metabotropic glutamate receptors negatively regulates the stimulation of inositol phospholipid hydrolysis mediated by 5-hydroxytryptamine2A serotonin receptors in the frontal cortex of living mice.
    Molinaro G; Traficante A; Riozzi B; Di Menna L; Curto M; Pallottino S; Nicoletti F; Bruno V; Battaglia G
    Mol Pharmacol; 2009 Aug; 76(2):379-87. PubMed ID: 19439499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Effects of LY3020371, a Potent and Selective Metabotropic Glutamate (mGlu) 2/3 Receptor Antagonist, and Ketamine, a Noncompetitive
    Witkin JM; Mitchell SN; Wafford KA; Carter G; Gilmour G; Li J; Eastwood BJ; Overshiner C; Li X; Rorick-Kehn L; Rasmussen K; Anderson WH; Nikolayev A; Tolstikov VV; Kuo MS; Catlow JT; Li R; Smith SC; Mitch CH; Ornstein PL; Swanson S; Monn JA
    J Pharmacol Exp Ther; 2017 Apr; 361(1):68-86. PubMed ID: 28138040
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of AMPA receptor stimulation and TrkB signaling in the antidepressant-like effect of ketamine co-administered with a group II mGlu receptor antagonist, LY341495, in the forced swim test in rats.
    Pałucha-Poniewiera A; Podkowa K; Pilc A
    Behav Pharmacol; 2019 Sep; 30(6):471-477. PubMed ID: 30724804
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice.
    Ago Y; Yano K; Araki R; Hiramatsu N; Kita Y; Kawasaki T; Onoe H; Chaki S; Nakazato A; Hashimoto H; Baba A; Takuma K; Matsuda T
    Neuropharmacology; 2013 Feb; 65():29-38. PubMed ID: 23022081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
    Liechti ME; Markou A
    Eur J Pharmacol; 2007 Jan; 554(2-3):164-74. PubMed ID: 17113075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of an mGlu2/3 receptor antagonist on depressive behavior induced by withdrawal from chronic treatment with methamphetamine.
    Iijima M; Koike H; Chaki S
    Behav Brain Res; 2013 Jun; 246():24-8. PubMed ID: 23473878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR.
    Sanger H; Hanna L; Colvin EM; Grubisha O; Ursu D; Heinz BA; Findlay JD; Vivier RG; Sher E; Lodge D; Monn JA; Broad LM
    Neuropharmacology; 2013 Mar; 66():264-73. PubMed ID: 22659090
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidepressant-like effect of ascorbic acid is associated with the modulation of mammalian target of rapamycin pathway.
    Moretti M; Budni J; Freitas AE; Rosa PB; Rodrigues AL
    J Psychiatr Res; 2014 Jan; 48(1):16-24. PubMed ID: 24209999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge.
    Lorrain DS; Schaffhauser H; Campbell UC; Baccei CS; Correa LD; Rowe B; Rodriguez DE; Anderson JJ; Varney MA; Pinkerton AB; Vernier JM; Bristow LJ
    Neuropsychopharmacology; 2003 Sep; 28(9):1622-32. PubMed ID: 12825094
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats.
    Koike H; Iijima M; Chaki S
    Pharmacol Biochem Behav; 2013 Jun; 107():20-3. PubMed ID: 23578563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. mTOR activation is required for the antidepressant effects of mGluR₂/₃ blockade.
    Dwyer JM; Lepack AE; Duman RS
    Int J Neuropsychopharmacol; 2012 May; 15(4):429-34. PubMed ID: 22114864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.